Royalty Pharma
RPRX
455 hedge funds and large institutions have $12.4B invested in Royalty Pharma in 2025 Q2 according to their latest regulatory filings, with 76 funds opening new positions, 172 increasing their positions, 156 reducing their positions, and 64 closing their positions.
356% more call options, than puts
Call options by funds: $81.6M | Put options by funds: $17.9M
23% more capital invested
Capital invested by funds: $10.1B → $12.4B (+$2.3B)
19% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 64
10% more repeat investments, than reductions
Existing positions increased: 172 | Existing positions reduced: 156
6.84% more ownership
Funds ownership: 74.49% → 81.34% (+6.8%)
2% more funds holding
Funds holding: 447 → 455 (+8)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$725M |
| 2 |
Morgan Stanley
New York
|
+$185M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$153M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$53.5M |
| 5 |
Amundi
Paris,
France
|
+$51.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$264M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
-$74M |
| 3 |
Two Sigma Advisers
New York
|
-$68.2M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$65.7M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$55.1M |
RPRX Hedge Fund Activity: Q2 2025 in Review
455 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2025, worth a combined $12.4B — up 23% from $10.1B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new RPRX positions and 64 closed out — a net gain of 12 holders — while 172 added to existing stakes and 156 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $725M. The largest seller was Viking Global Investors, cutting an estimated $264M.
- 455 institutional investors held Royalty Pharma (RPRX) as of Q2 2025, up from 447 in Q1 2025.
- Funds reported $12.4B of Royalty Pharma stock for Q2 2025, up 23% quarter-over-quarter.
- 76 funds opened new Royalty Pharma positions in Q2 2025 and 64 closed out, a net change of +12 holders.
- The largest Royalty Pharma buyer in Q2 2025 was Capital International Investors, an estimated $725M added.
- The largest Royalty Pharma seller in Q2 2025 was Viking Global Investors, an estimated $264M sold.
Based on aggregated 13F filings for Q2 2025.